Huabo goes pivotal with bispecific VEGF trap
The company takes a PD-L1 x VEGF asset into phase 3.
Two more companies try to outdo Rybrevant
After Genmab’s exit two more ADCs enter human trials.
Novartis perseveres with pelabresib
A new phase 3, Manifest-3, will start in April to support US filing.
Moderna investors prepare for a phase 3 reveal
Intismeran autogene’s Interpath-001 trial reads out this year.
Neok plays a high-risk bispecific conjugate game
Armed with $75m the company takes a risky asset into the clinic.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
